Verified email-pattern data for Rarecan is currently limited. You can still use the company insights and contact sections below.
Researchers around the world are looking at better ways to diagnose and treat rare cancers.
Today there are 740 global life sciences companies investing in 950 products that include a rare cancer target. This translates into an accelerating number of clinical trials taking place, all requiring access to consenting patients, secure data, and bio-samples. If not readily available to researchers, desperately needed progress in this area becomes at-risk.
RareCan offers a rich source of valuable information to researchers, providing rapid, joined up access to patients, data and bio-samples. We represent an unparalleled opportunity to accelerate research into rare cancers now and in the future.
By connecting consenting patients with leading researchers, RareCan is pioneering a new platform of a large and growing patient community with a BioResource, giving researchers access to tissue and blood samples, as well as genetic data, to improve the prevention, diagnosis or treatment of rare cancers. This reduces the time taken to provide samples for research purposes from months to weeks.
The platform enables researchers to find the exact patients or tissue needed for their rare cancer targets. This means RareCan can build precise cohorts of trial participants, and enable the delivery of histology-independent trials, targeting genetic mutations common across a range of different rare cancers, including solid tumour types associated with cancers such as breast, colorectal and pancreatic.
RareCan is the first and only company in the market to bring together ‘consent to contact’ patient recruitment, an abundance of data to ensure accurate screening, and access to bio-samples and genetics. This is the future of clinical research.
RareCan is supported by a network of NHS Trusts, including Newcastle Hospitals NHS Foundation Trust, and patient organisations, including GIST Cancer UK.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Hexham, Gb
- in****@****can.com
- Industry
- Research
- Website
- rarecan.com
- Keywords
- London.
- HQ
- Hexham
Rarecan Questions
RareCan's website is rarecan.com
RareCan's LinkedIn profile is https://uk.linkedin.com/company/rarecan
RareCan has
7 employees.
View email and phone details for 7
employees at RareCan.
RareCan's industry is
Research
RareCan's top competitors are
Inherit Health Ltd,
Inditise,
Future Medicine Ai,
Zooz Drinks,
Cancer52,
Fibromyalgia Treatment & Learning Center,
Chestnut Biopolymers,
The Elders Council Of Newcastle,
Inditex,
Cardiatec Bio.
RareCan's support email address is info@rarecan.com
RareCan's categories are Research
RareCan's founding year is 2019
Top RareCan Employees
-
Tejal Jain
Social Media Officer At Rarecan
Newcastle Upon Tyne, England, United Kingdom, United Kingdom -
-
Piers Kotting
Ceo @ Rarecan | Precision Oncology…
Greater Exeter Area, United Kingdom, United Kingdom3hotmail.com, ucl.ac.uk, nihr.ac.uk -
Andy Hall
Chief Scientific Officer @ Rarecan |…
Newcastle Upon Tyne, England, United Kingdom, United Kingdom4ncl.ac.uk, ncl.ac.uk, hta.gov.uk, nhs.net
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.